BR112017011078A2 - composições de kiwi ouro e métodos de preparação e uso das mesmas - Google Patents

composições de kiwi ouro e métodos de preparação e uso das mesmas

Info

Publication number
BR112017011078A2
BR112017011078A2 BR112017011078A BR112017011078A BR112017011078A2 BR 112017011078 A2 BR112017011078 A2 BR 112017011078A2 BR 112017011078 A BR112017011078 A BR 112017011078A BR 112017011078 A BR112017011078 A BR 112017011078A BR 112017011078 A2 BR112017011078 A2 BR 112017011078A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
kiwi
preparation
gold kiwi
Prior art date
Application number
BR112017011078A
Other languages
English (en)
Other versions
BR112017011078B1 (pt
Inventor
Ansell Juliet
Blatchford Paul
Original Assignee
Anagenix Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anagenix Ip Ltd filed Critical Anagenix Ip Ltd
Publication of BR112017011078A2 publication Critical patent/BR112017011078A2/pt
Publication of BR112017011078B1 publication Critical patent/BR112017011078B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/01—Instant products; Powders; Flakes; Granules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

a presente divulgação abrange composições preparadas de kiwi. em particular, a invenção abrange composições preparadas das variedades de kiwi ouro de actinidia chinensis. são também englobados métodos para preparar estas composições. além disso, são englobados ainda métodos de uso destas composições, em particular, para tratar ou prevenir transtornos do sistema gastrointestinal, incluindo entre outros: inflamação, constipação, irregularidade intestinal, desequilíbrios da microbiota, síndrome do intestino irritável e doença inflamatória intestinal.
BR112017011078-4A 2014-11-28 2015-11-27 usos de uma composição preparada a partir de kiwi ouro seco BR112017011078B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NZ70245414 2014-11-28
NZ702454 2014-11-28
NZ70640515 2015-03-27
NZ706405 2015-03-27
PCT/NZ2015/050200 WO2016085356A1 (en) 2014-11-28 2015-11-27 Gold kiwifruit compositions and methods of preparation and use therefor

Publications (2)

Publication Number Publication Date
BR112017011078A2 true BR112017011078A2 (pt) 2017-12-26
BR112017011078B1 BR112017011078B1 (pt) 2021-05-11

Family

ID=56074755

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011078-4A BR112017011078B1 (pt) 2014-11-28 2015-11-27 usos de uma composição preparada a partir de kiwi ouro seco

Country Status (10)

Country Link
US (4) US10512663B2 (pt)
EP (1) EP3223838A4 (pt)
JP (2) JP7330667B2 (pt)
KR (2) KR20230156436A (pt)
CN (3) CN106999523A (pt)
BR (1) BR112017011078B1 (pt)
CA (2) CA3200468A1 (pt)
MY (1) MY188290A (pt)
NZ (1) NZ732197A (pt)
WO (1) WO2016085356A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512663B2 (en) * 2014-11-28 2019-12-24 Anagenix Ip Limited Gold kiwifruit compositions and methods of preparation and use therefor
KR101833348B1 (ko) * 2016-12-26 2018-03-02 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 유방암 진단방법
KR101833504B1 (ko) * 2016-12-26 2018-03-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 폐암 진단방법
KR101940426B1 (ko) * 2016-12-28 2019-01-18 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법
KR101942197B1 (ko) 2016-12-28 2019-01-24 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 전립선질환 진단 방법
US11413318B2 (en) * 2017-06-06 2022-08-16 Sami-Sabinsa Group Limited Compositions and methods for management of atrophic gastritis and colitis
US10881675B2 (en) 2017-10-11 2021-01-05 Jennifer L. Gu Gut health compositions
KR102130485B1 (ko) * 2017-10-13 2020-07-06 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 알츠하이머치매 진단방법
KR102007786B1 (ko) * 2017-10-18 2019-08-07 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 두경부암 진단방법
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
KR101940950B1 (ko) * 2018-01-23 2019-01-21 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 담관암 진단방법
KR101944662B1 (ko) * 2018-02-14 2019-02-01 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 뇌졸중 진단방법
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CN109288104B (zh) * 2018-11-12 2023-09-01 方家铺子（莆田）绿色食品有限公司 一种桂圆鲜果挂黄处理设备及其处理方法
EP3911179A2 (en) 2019-01-18 2021-11-24 CP Kelco U.S., Inc. Prebiotic composition and its use
CN110279814A (zh) * 2019-06-10 2019-09-27 湖北虹玮农业有限公司 一种用于中老年慢性便秘的功能食品
US11684645B2 (en) * 2019-11-26 2023-06-27 Tci Co., Ltd. Actinidia chinensis Planch ferment and use thereof
WO2022115709A2 (en) * 2020-11-30 2022-06-02 January, Inc. Methods and composition for treating metabolic syndrome
US20220233151A1 (en) * 2021-01-22 2022-07-28 Ethicon Llc Bariatric surgery post-surgical monitoring
KR102543549B1 (ko) * 2021-01-26 2023-06-15 주식회사 다솔마임마케팅사업부 칼라만시 발포정 및 그 제조 방법
CN113521109A (zh) * 2021-06-28 2021-10-22 广州知易生物科技有限公司 解纤维素拟杆菌在预防和/或治疗炎症性肠病中的应用
CN116076711A (zh) * 2021-11-05 2023-05-09 百岳特生物技术（上海）有限公司 益生质组合物及其用途
US20230144246A1 (en) * 2021-11-05 2023-05-11 Tci Co., Ltd. Probiotic composition and its method for improving intestinal tract of subject in need thereof
CA3238788A1 (en) 2021-11-22 2023-05-25 Eric Michael Schott Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
KR102536627B1 (ko) * 2022-09-30 2023-05-30 (주)바이텍 키위 발효물을 포함하는 알코올성 간손상 예방 또는 개선용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US22355A (en) 1858-12-21 sherwood
JP2750767B2 (ja) 1990-02-21 1998-05-13 雪印乳業株式会社 新規糖アルコール
CN1107308A (zh) * 1994-02-25 1995-08-30 中国癌症研究基金会 猕猴桃天然营养口服液
JP3246296B2 (ja) 1995-11-09 2002-01-15 宇部興産株式会社 半溶融金属の成形方法
JPH10313822A (ja) 1997-05-20 1998-12-02 Pola Chem Ind Inc 腸内細菌叢改善剤及びそれを含有する組成物
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
USPP22355P3 (en) * 2009-06-30 2011-12-20 Zespri Group Limited Kiwifruit plant named ‘ZESY002’
MY162344A (en) * 2010-01-28 2017-06-15 Ab-Biotics S A Probiotic composition for use in the treatment of bowel inflammation
US10512663B2 (en) * 2014-11-28 2019-12-24 Anagenix Ip Limited Gold kiwifruit compositions and methods of preparation and use therefor

Also Published As

Publication number Publication date
CN106999523A (zh) 2017-08-01
CN116270773A (zh) 2023-06-23
JP2022078050A (ja) 2022-05-24
JP2017537156A (ja) 2017-12-14
CN116763830A (zh) 2023-09-19
EP3223838A1 (en) 2017-10-04
US20240091291A1 (en) 2024-03-21
KR20230156436A (ko) 2023-11-14
CA2967263A1 (en) 2016-06-02
KR102599549B1 (ko) 2023-11-06
NZ732197A (en) 2022-07-01
US20220105145A1 (en) 2022-04-07
JP7330667B2 (ja) 2023-08-22
MY188290A (en) 2021-11-25
EP3223838A4 (en) 2018-08-01
JP7471668B2 (ja) 2024-04-22
US20200197460A1 (en) 2020-06-25
US20170326190A1 (en) 2017-11-16
KR20170088970A (ko) 2017-08-02
US10512663B2 (en) 2019-12-24
CA3200468A1 (en) 2016-06-02
WO2016085356A1 (en) 2016-06-02
US11090348B2 (en) 2021-08-17
US11642386B2 (en) 2023-05-09
BR112017011078B1 (pt) 2021-05-11

Similar Documents

Publication Publication Date Title
BR112017011078A2 (pt) composições de kiwi ouro e métodos de preparação e uso das mesmas
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
WO2017011820A3 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2016033439A3 (en) Compositions and methods for the treating an inflammatory disease or disorder
WO2016077397A3 (en) Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
WO2016014434A3 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112016016580A2 (pt) Polissacarídeos capsulares de streptococcus pneumoniae e conjugados dos mesmos
WO2015085318A3 (en) Targeted adaptive vaccines
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
EA201890111A1 (ru) Замещенные производные оксопиридина
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
MX2017001971A (es) Composiciones antimetanogenicas y sus usos.
MX2022003706A (es) Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
WO2016098079A3 (en) Compositions and methods for antibodies targeting bmp6
WO2015164392A3 (en) Novel antii-rnf43 antibodies and methods of use
PH12016501366A1 (en) Novel anti-baff antibodies
DK3380529T3 (da) Aktiverede pektinholdige biomassesammensætninger, produkter og fremgangsmåder til fremstilling heraf
BR112015028338A2 (pt) métodos de diagnóstico ou de auxílio no diagnóstico e de tratamento da doença inflamatória intestinal
WO2015177175A3 (en) Novel specific-binding polypeptides and uses thereof
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
WO2015031778A3 (en) Compositions and methods for the treatment or prevention of tuberculosis
BR112017009510A2 (pt) composições compreendendo ciclosporina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/11/2015, OBSERVADAS AS CONDICOES LEGAIS.